262368-30-9

Basic information

• Product Name: N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide
• Synonyms: N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide;N-(4-Aminophenyl)-N,4-dimethyl-1-piperazineacetamide;N-[(4-methyl-piperazin-1-yl)methylcarbonyl]-N-methyl-p-phenylendiamine;-N-methyl-2-(4-methylpiperazin-1-yl);Nintedanib Intermediate 2
• CAS NO: 262368-30-9
• Molecular Formula: C₁₄H₂₂N₄O
• Molecular Weight: 262
• EINECS: 919-251-0
• Product Categories: Intermediate of BIBF-1120 and PKI587
• Mol File: 262368-30-9.mol
• Article Data: 19

Chemical Properties

• Melting Point: 148-150
• Boiling Point: 434.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.151
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 7.43±0.10(Predicted)
• CAS DataBase Reference: N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide(262368-30-9)
• EPA Substance Registry System: N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide(262368-30-9)

Safety Data

• Hazardous Substances Data: 262368-30-9(Hazardous Substances Data)

Usage

Uses

N-(4-Aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide acts as a reagent for the preparation, angiokinase inhibitory, antitumor activity and pharmacokinectic properties of deuterated derivatives of nintedanib.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 79-04-9 chloroacetyl chloride 
• 350-46-9 4-Fluoronitrobenzene 
• 74-89-5 methylamine 
• 2653-16-9 2-chloro-N-methyl-N-(4-nitrophenyl)acetamide 
• 1139453-98-7 N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)-acetamide 
• 100-15-2 N-methyl(p-nitroaniline) 
• 586-78-7 para-nitrophenyl bromide 

Downstream Products

• 656247-17-5 nintedanib 
• 1160294-26-7 nintedanib 
• 1448874-96-1 (Z)-methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-6-carboxylate 
• 1448875-02-2 (Z)-methyl 3-(((4-((2-(ethyl(methyl)amino)-2-oxoethyl)(methyl)amino)phenyl)amino)(phenyl)methylene)-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-6-carboxylate 

Relevant articles and documents

Synthesis of the Kinase Inhibitors Nintedanib, Hesperadin, and Their Analogues Using the Eschenmoser Coupling Reaction

A novel synthetic approach involving an Eschenmoser coupling reaction of substituted 3-bromooxindoles (H, 6-Cl, 6-COOMe, 5-NO2) with two substituted thiobenzanilides in dimethylformamide or acetonitrile was used for the synthesis of eight kinase inhibitor

Preparation method of nintedanib key intermediate

The invention provides a preparation method of a nintedanib key intermediate, and belongs to the technical field of synthesis of medical intermediates. The first preparation method comprises the following steps: carrying out a nitro reduction reaction on a compound IV by taking an alcohol reagent or tetrahydrofuran as a solvent, taking hydrazine hydrate as a reducing agent and taking palladium carbon (Pd/C) as a catalyst until the nitro reduction reaction is complete, performing filtering to remove the catalyst under the protection of nitrogen, performing desolventizing to remove the solvent, performing dissolving by using dichloromethane, performing filtering to remove impurities, and performing desolventizing to obtain a compound I; the second method comprises the following steps: carrying out a nitro reduction reaction on a compound IV by taking hydrazine hydrate as a reducing agent and anhydrous ferric trichloride and activated carbon as catalysts until the nitro reduction reaction is complete, performing performing filtering to remove the catalyst, performing desolventizing to remove the solvent, dissolving dichloromethane, drying anhydrous sodium sulfate, performing filtering, and performing desolventizing to obtain a compound I. The preparation method provided by the invention is high in yield, strong in operability and high in safety, belongs to an environment-friendly process, and is suitable for industrial large-scale production.

INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.